Abstract
We evaluated the question of whether the chemosensitizers verapamil and quinine given orally to breast cancer patients failing combination chemotherapy alone would result in additional clinical responses. In vitro studies reported here showed verapamil sensitization of Adriamycin resistance in 18.8% of fresh human breast cancer specimens tested. Patients (27) were first treated with cyclophosphamide, vincristine, Adriamycin and dexamethasone (CVAD) alone. Verapamil and quinine were added in patients with tumors failing to respond or progressing on CVAD alone. Following treatment with CVAD alone there were no complete remissions and 3 patients (11%) developed partial remissions lasting 5.5, 8, 10.5 months. With the addition of verapamil and quinine to the CVAD regimen, one patient (4%) developed a complete remission of 11.8 months duration and 4 additional patients (15%) developed partial remissions lasting 2.8, 17.3, 19 and > 40 months. Thus, the overall rate of CVAD sensitization by verapamil and quinine was 19%. Treatment with CVAD plus verapamil and quinine was generally well tolerated with observed toxicities including: myelosuppression, neuropathy, Cushingoid symptoms and tinnitus and/or dizziness due to quinine. We conclude that addition of the non-cytotoxic chemosensitizers verapamil and quinine to CVAD in patients failing CVAD alone results in additional clinical responses in a small percentage of patients, some with long term durations. The results of this study lend credence to the notion that non-cytotoxic chemosensitizers can enhance the clinical activity of combination chemotherapy and the search for more effective and less toxic chemosensitizers continues.
Similar content being viewed by others
References
Henderson IC: Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases. J.B. Lippincott Co, Philadelphia, 1991, p 604–665
Gerlach JH, Kartner N, Bell DR, Ling V: Multidrug resistance. Cancer Surveys 5: 25–46, 1986
Pastan I, Gottesman M: Multiple-drug resistance in human cancer. N Engl J Med 316: 1388–1393, 1987
Merkel DE, Fuqua SAW, Tandon AK, Hill SM, Buzdar AU, McGuire WL: Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. J Clin Oncol 7: 1129–1136, 1989
Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M: P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 60: 815–818, 1989
Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M: Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 21: 787–791, 1990
Wishart GC, Plumb JA, Going JJ, McNicol AM, McArdle CS, Tsuruo T, Kaye SB: P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 62: 758–761, 1990
Sanfilippo O, Ronchi E, De Marco C, Di Fronzo G, Silvestrini R: Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur J Cancer 27: 155–158, 1991
Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, Plagne R, Chassagne J: Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83: 111–116, 1991
Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, Roe DJ, Trent JM: Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer 63: 923–929, 1991
Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS: Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 81: 696–701, 1989
Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE: Synergistic inhibition by verapamil and quinine of p-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 2: 348–354, 1991
Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I: Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 88: 547–551, 1991
Salmon SE, Hamburger AW, Soehnlen BJ, Durie BGM, Alberts DS, Moon TE: Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 298: 1321–1327, 1978
Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP: Multidrug-resistant myeloma — Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78: 44–50, 1991
Kressner BE, Morton RR, Martens AE, Salmon SE, Von Hoff DD, Soehnlen B: Use of an image analysis system to count colonies and stem cell assays of human tumors. Progress in Clinical and Biological Research 179–193, 1980
Merkel DE, Fuqua SAW, McGuire WL: P-glycoprotein in breast cancer. Cancer Treat Res 48: 97–105, 1989
Merkel DE, Fuqua SA, Hill SM, Mcguire WL: P-glycoprotein gene amplification or overexpression is not detected in clinical breast cancer specimens. Prog Clin Biol Res 276: 61–73, 1988
Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415–424, 1989
Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J Clin Oncol 9(1): 17–24, 1991
Ries F, Dicato M: Treatment of advanced and refractory breast cancer with doxorubicin, vincristine and continuous infusion of verapamil. A phase I–II clinical trial. Medical Oncology & Tumor Pharmacotherapy 8: 39–43, 1991
Mross K, Bohn C, Edler L, Jonat W, Queisser W, Heidemann E, Goebel M, Hossfeld DK: Randomized phase II study of single-agent epirubicin verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Annals of Oncology 4: 45–50, 1993
Wishart GC, Bissett D, Paul J, Jodrell D, Harnett A, Habeshaw T, Kerr DJ, Macham MA, Soukop M, Leonard RCF, Knepil J, Kaye SB: Quinidine as a resistance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial. J Clin Oncol 12: 1771–1777, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Taylor, C.W., Dalton, W.S., Mosley, K. et al. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer. Breast Cancer Res Treat 42, 7–14 (1997). https://doi.org/10.1023/A:1005716214718
Issue Date:
DOI: https://doi.org/10.1023/A:1005716214718